Compare NVAX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | BBNX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1995 | 2025 |
| Metric | NVAX | BBNX |
|---|---|---|
| Price | $6.60 | $29.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $10.78 | ★ $28.09 |
| AVG Volume (30 Days) | ★ 3.5M | 672.2K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $1,064,651,000.00 | $88,570,000.00 |
| Revenue This Year | $58.91 | $52.13 |
| Revenue Next Year | N/A | $36.16 |
| P/E Ratio | $3.17 | ★ N/A |
| Revenue Growth | 20.27 | ★ 67.01 |
| 52 Week Low | $5.01 | $8.89 |
| 52 Week High | $11.55 | $32.71 |
| Indicator | NVAX | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 56.97 |
| Support Level | $6.43 | $28.00 |
| Resistance Level | $6.84 | $30.50 |
| Average True Range (ATR) | 0.21 | 1.82 |
| MACD | 0.04 | -0.26 |
| Stochastic Oscillator | 24.78 | 39.46 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.